iShares 1 3 Year Treasury Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: iShares 1 3 Year Treasury Bond ETF is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 1 3 Year Treasury Bond ETF for 63 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SHY | ZBH | |
|---|---|---|
Market Cap | $26.68B | $16.95B |
Volume | 4,077,691 | 2,505,240 |
Sector | Fixed Income | Health |
52-Week High | $83.18 | $103.98 |
52-Week Low | $81.05 | $79.58 |
Typical Hold Time | 63 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
SHY trades at $81.20 with minimal daily movement (+0.05%), showing stability amid broader bond market volatility. Technical indicators signal a bearish trend with moving averages pointing downward, though oscillators remain neutral. Recent dividend payments of $0.24-$0.25 per share provide consistent income, but key financial ratios are unavailable for fundamental assessment. The ETF faces headwinds from rising Treasury yields and persistent inflation pressures affecting fixed income markets.
Outlook remains cautious as SHY navigates a challenging interest rate environment. The fund benefits from short-duration focus during Fed tightening cycles but faces pressure from bond market selloffs. Investment opportunity lies in yield advantage over cash, while risks include further rate hikes and prolonged inflation. Institutional sentiment appears mixed given conflicting technical signals and macroeconomic uncertainty.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →